I don't know, Ratfink - all of those trials reviewed in various meta-analyses of MSCs in treatment for COVID ARDS have universally indicated that their anti-inflammatory characteristics are just what the doctor ordered to tamp down the illness.
As well, the results in the NIH trial for <65s on Dex were pretty stellar, too, and are right in line with that multitude of trials.
Personally, I reckon NVS' decision is more a commercial one that one based on the science. They have had the data FOREVER. I just cannot believe they FINALLY decided that it showed Rem-L didn't work and was unlikely to get approved. Sounds like a bit of tosh to me.
At the end, we have NO idea why NVS made the call - and particularly whether it was NVS scientists that made the call. Could just have easily been NVS business people that made the decision.
Ann: MSB and Oaktree Conclude Refinancing of Senior Debt Facility, page-203
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.060(5.33%) |
Mkt cap ! $1.216B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.14 | $1.07 | $5.556M | 5.065M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 193123 | $1.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 300057 | 2 |
View Market Depth
| Last trade - 16.10pm 05/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.07 |
Change
-0.060 ( 5.22 %) |
||||
| Open | High | Low | Volume | ||
| $1.13 | $1.14 | $1.07 | 1328053 | ||
| Last updated 15.59pm 05/06/2024 ? | |||||
| MSB (ASX) Chart |